Fil LTD Incyte Corp Transaction History

Fil LTD

$103 Billion
Q3 2024

A detailed history of Fil LTD transactions in Incyte Corp stock. As of the latest transaction made, Fil LTD holds 3,571 shares of INCY stock, worth $257,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,571

Previous 7,637 53.24%

Holding current value

$257,219

Previous $462,000 48.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $233,103 - $278,968	-4,066 Reduced 53.24%	3,571 $236,000
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $390,861 - $486,858	7,637 New	7,637 $462,000
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $559 - $612	-7 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$80.74 - $97.7 $161 - $195	-2 Reduced 22.22%	7 $1,000
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $5,192 - $7,625	-70 Reduced 88.61%	9 $1,000
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $10.2 Million - $13.9 Million	-161,277 Reduced 99.95%	79 $6,000
Q4 2019 Feb 07, 2020	SELL	$73.04 - $95.72 $6.93 Million - $9.08 Million	-94,853 Reduced 37.02%	161,356 $14.1 Million
Q3 2019 Nov 13, 2019	BUY	$72.82 - $86.52 $3.07 Million - $3.65 Million	42,189 Added 19.71%	256,209 $19 Million
Q2 2019 Aug 13, 2019	BUY	$73.52 - $88.7 $5.34 Million - $6.44 Million	72,574 Added 51.31%	214,020 $18.2 Million
Q1 2019 May 13, 2019	BUY	$63.56 - $88.17 $8.99 Million - $12.5 Million	141,446 New	141,446 $12.2 Million
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $234 - $279	-4 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$61.75 - $74.23 $247 - $296	4 New	4 $0

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Account